Used in cancer immunotherapy research to block the SIRPA-CD47 interaction, enhancing macrophage-mediated phagocytosis of tumor cells. This antibody supports the development of therapies aimed at improving immune system recognition and destruction of cancer cells, particularly in hematologic malignancies and solid tumors. It is also utilized in laboratory studies to investigate immune checkpoint pathways and myeloid cell function.